You are here

Eli Lilly

Is Eli Lilly Overpaying for Loxo Oncology?

Motley Fool

Tue, 01/8/19 - 09:30 am

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics

Stat

Mon, 01/7/19 - 10:09 am

Does Pfizer Have A Multibillion-Dollar Replacement For Opioids?

Investors Business Daily

Mon, 12/31/18 - 12:15 pm

Lilly, Aduro Biotech in Immunotherapy Alliance

Contract Pharma

Thu, 12/20/18 - 11:46 am

autoimmune disease

drug development

Aiming to shed last-place rep, Eli Lilly touts its PhIII pipeline and promises a faster game in R&D

Endpoints

Wed, 12/19/18 - 10:06 am

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Reuters

Mon, 12/17/18 - 08:15 pm

psoriatic arthritis

clinical trials

Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets

Endpoints

Mon, 12/17/18 - 09:00 am

Hydra Biosciences

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus

Fierce Pharma

Thu, 12/13/18 - 12:24 pm

Boehringer Ingelheim

Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug

Fierce Biotech

Wed, 12/12/18 - 11:50 am

Alzheimer's disease

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Xtalks

Mon, 12/10/18 - 07:07 pm

clinical trials

Multiple Myeloma

adaptive trial design

Eli Lilly's former drug yields Phase 2 win for Vanda Pharma

Biopharma Dive

Tue, 12/4/18 - 07:17 pm

Vanda Pharmaceuticals

clinical trials

Rising fear among Asians leads Eli Lilly to rethink employee groups

Indianpolis Business Journal

Sat, 11/24/18 - 01:25 pm

Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials

Fierce Biotech

Mon, 11/19/18 - 04:46 pm

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Mon, 11/19/18 - 11:29 am

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Eli Lilly Could Sell Some Older China Assets for up to $300 Million

BioSpace

Fri, 11/16/18 - 07:55 pm

After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer

Fierce Pharma

Fri, 11/16/18 - 12:10 pm

non-small cell lung cancer

7 drugs that raised eyebrows in Q3

Biopharma Dive

Thu, 11/15/18 - 11:50 pm

Clovis Oncology

Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache

Fierce Pharma

Thu, 11/15/18 - 11:37 pm

cluster headaches

breakthrough therapies

Eli Lilly backs away from Bace but not from novel Alzheimer’s targets

EP Vantage

Thu, 11/15/18 - 09:48 am

drug development

Alzheimer's disease

BACE inhibitors

Biotech Eli Lilly files for FDA approval of migraine drug lasmiditan

Fierce Biotech

Wed, 11/14/18 - 04:50 pm

Pages